Please login to the form below

Not currently logged in
Email:
Password:

Alexion

This page shows the latest Alexion news and features for those working in and with pharma, biotech and healthcare.

Abingworth raises $315m to expand hunt for promising biotechs

Abingworth raises $315m to expand hunt for promising biotechs

The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for

Latest news

More from news
Approximately 22 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • European venture funding for the life science sector European venture funding for the life science sector

    Eli Lilly, Novartis and Alexion, should ensure a healthy M&A appetite going forward.

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)

  • Deal Watch August 2016 Deal Watch August 2016

    This high premium and the one for Cynapsys (see below) has led to speculation that other potential target mid cap biotech companies such as Vertex, BioMarin and Alexion could command higher

  • Deal Watch October 2015 Deal Watch October 2015

    Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co,

  • Pharma deals in May 2015 Pharma deals in May 2015

    Topping the table with a headline value of $8.4bn was the acquisition of Synageva BioPharma by Alexion. ... With a similar headline value to Synageva/Alexion and building on its acquisition plans was the purchase of Par Pharmaceuticals by Endo.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • Abeona Therapeutics names CEO Abeona Therapeutics names CEO

    Abeona Therapeutics names CEO. Carsten Thiel joins the biopharma from Alexion. ... Formerly serving as Alexion Pharmaceutical’s executive vice president and chief commercial officer, Thiel brings experience in leading commercial operations to his new

  • Amryt Pharma appoints Jordi Casals as head of Europe Amryt Pharma appoints Jordi Casals as head of Europe

    Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.

  • Alexion Pharmaceuticals adds to its board Alexion Pharmaceuticals adds to its board

    Alexion Pharmaceuticals adds to its board. Judith Reinsdorf recently worked at Johnson Controls. ... David Brennan, chairman of the board, said: “We are pleased to welcome Judy to Alexion ’s board of directors.

  • Alexion appoints new senior VP for EMEAC region Alexion appoints new senior VP for EMEAC region

    Alexion appoints new senior VP for EMEAC region. Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. ... Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region.

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was responsible for all aspects of clinical trial development.

More from appointments
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics